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Abstract 
Cyclin D1 promotes nuclear DNA synthesis through phosphorylation and 
inactivation of the pRb tumor suppressor. Herein, we show that mitochondrial size and 
activity as measured by Mitotracker were reversed by the expression of cyclin D1 in a 
Cdk-dependent manner. Nuclear Respiratory Factor 1 (NRF-1), which induces nuclear-
encoded mitochondrial genes, was repressed in expression and activity by cyclin D1. 
Association of NRF-1 with cyclin D1 was demonstrated by co-immunoprecipitation and 
mammalian two-hybrid assays. It was shown that the cyclin D1-dependent kinase 
phosphorylates NRF-1 at S47. Cyclin D1 abundance thus coordinates nuclear DNA 
synthesis and mitochondrial function. 
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Introduction 
Mitochondria function as central components of mammalian cellular survival 
through production of ATP and re-oxidized NAD.  They also govern cell death through 
mitochondrial membrane-dependent cellular death signals.  The mammalian cell contains 
103-104 copies of mitochondrial DNA (mtDNA), 2 ribosomal RNAs (rRNA) and 
22 transfer RNAs (tRNA) required for mitochondrial protein synthesis. Nuclear-encoded 
genes regulate mitochondrial biogenesis and function, respiratory genes, the citric acid 
cycle and upstream glycotic steps and amino acid metabolism (1). Mitochondrial 
transcription factor A (mtTFA, also known as Tfam) and nuclear respiratory factors 
(NRFs) (2, 3) regulate nuclear genes governing mitochondrial function and promoters 
within the mitochondrial D-loop region, thereby promoting replication and transcription 
of mtDNA. mtTFA is essential for yeast mtDNA maintenance (4) and mtTFA-/- mice have 
reduced mitochondrial respiratory chain function with depleted mtDNA and oxidative 
phosphorylation (2).  
NRF-1 increases mitochondrial respiratory capacity, induces expression of a 
subset of genes governing mitochondrial activity in a cell-type specific manner (reviewed 
in (5)) and enhances mitochondrial responses to the PPARγ co-activator PGC-1 (6). 
NRF-1-independent mitochondrial gene expression pathways are regulated by PPARs, Sp 
1 and other factors. Although mitochondrial gene function is co-dependent upon the 
nuclear genome and mitochondrial activity alters nuclear gene expression (“retrograde 
communication” (7)), the mechanism coordinating nuclear DNA synthesis, growth 
responses and mitochondrial synthesis is unknown.  
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The cyclin D1 gene encodes a labile growth factor- and oncogene-inducible 
component of the holoenzyme that phosphorylates and inactivates the retinoblastoma 
protein (pRb), promoting nuclear DNA synthesis (8).  Cyclin D1-/- mouse embryo 
fibroblasts (MEFs) have a normal cell size and reduced DNA synthesis rates which can 
be rescued through introduction of cyclin D1 ((9) and data not shown). Cyclin D1-/- mice 
are resistant to oncogene-induced tumors of the skin, gut and mammary gland (10, 11). 
Herein we examined the possibility that cyclin D1 may also function to regulate 





To explore the role of cyclin D1 in mitochondrial gene function, we examined the 
mitochondrial size in cyclin D1-/- and littermate wild type control animals.  Mitochondrial 
size was increased 2- to 3-fold in proportion to cellular cytoplasm in hepatocytes (Fig. 
1A-D), as well as to the mammary gland adipocyte (Fig. 1E, F) in cyclin D1-/- mice.  
MitoTracker Deep Red 633, used to stain the functioning mitochondria in living cells 
through a fluorescent signal that is proportional to the mitochondrial activity, showed 
increased mitochondrial activity in cyclin D1-deficient MEFs, hepatocytes, and bone 
marrow macrophages compared with cyclin D1-expressing cells from littermate control 
animals (Fig. 1G). Cyclin D1 wild-type and mutant cDNAs were further transduced by 
retroviral infection into cyclin D1-/- MEFs in the MCSV-IRES-GFP vector to allow GFP 
sorting (Fig. 2A).  Mitochondrial function, assessed using MitoTracker (6), was 
conducted one week after viral transduction.  Cyclin D1 inhibited mitochondrial function 
52% (Fig. 2A) and also induced DNA synthesis (16% to 52%).  Furthermore, the pRb-
binding-deficient (GH), and C-terminal deletion (N4) of cyclin D1 also repressed 
mitochondrial function, whereas the Cdk-binding-defective KE mutant failed to inhibit 
mitochondrial activity or induce DNA synthesis, indicating the kinase-associated function 
of cyclin D1 inhibits mitochondrial function.  
Examination of the increased mitochondrial size in cyclin D1-/- hepatocytes 
showed the abundance of NRF-1 protein was increased 3-fold in cyclin D1-/- compared 
with wild type liver (Fig. 2B) while the NRF-1 coactivators, P/CAF and PGC-1 were 
unchanged (data not shown and Fig. 2B).  Addition of 10% serum to starved cells 
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induced cyclin D1 expression, and DNA synthesis, and reduced NRF-1 (Fig. 2C).  The 
NRF-1 target gene reporters, the D-loop reporter and the mtTFA promoter, were both 10-
fold more active in cyclin D1-/- cells compared with cyclin D1+/+ cells (Fig. 2D and E), 
suggesting that cyclin D1 inhibits D-loop transcriptional activity and mtTFA activity. 
Mutation of the mtTFA promoter NRF-1 or NRF-2, but not Sp1 sites, reduced promoter 
activity, indicating the enhanced mtTFA promoter activity in cyclin D1-/- cells involves 
increased NRF-1/NRF-2 activity (Fig. 2F). NRF-1 further enhanced while cyclin D1 
expression inhibited (without affecting expression of NRF-1), (data not shown) (Fig. 2G) 
4xNRE-LUC activity 2- to 3-fold in MCF-7 cells.  Cyclin D1 can repress activity of 
transcription factors, including PPARγ, in a Cdk-independent manner through HDAC 
recruitment (12). In contrast, cyclin D1 repression of 4xNRE-LUC activity was abrogated 
by point mutation of the Cdk-binding domain (cyclin D1 KE) (Fig. 2H), but not mutation 
of the pRb-binding domain (GH), the SRC-1 co-activator binding site (LLAA) or CAK 
association (T156A) site. The GH mutant induced DNA synthesis suggesting the reduced 
pRb-binding affinity of this mutant is insufficient to abrogate the DNA-synthesis, 
promoting function. A T286A mutant, which remains nuclear throughout the cell-cycle in 
cultured cells (13), repressed NRF-1 activity more than cyclin D1 wt.  Expression of the 
cyclin D1 mutants was similar to wild type in cultured cells (12). NRF-1 transactivation 
function, assessed with a heterologous DNA-binding domain, was repressed by cyclin 
D1, but not the KE mutant, again implicating cyclin D1-dependent kinase function in 
NRF-1 repression (data not shown). 
Cyclin D1 associated with NRF-1 in vivo Cyclin D1 co-precipitated Cdk4 and 
NRF-1, but not PGC-1 (12) in immunoprecipitation (IP)-Western blotting of murine liver 
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extracts (Fig. 3A). FLAG-tagged NRF-1, co-transfected into cells along with cyclin D1, 
co-precipitated cyclin D1 (Fig. 3B). NRF-1 wt was inserted into the MSCV-IRES-GFP 
vectors and used to transduce cyclin D1-/- and cyclin D1+/+ MEFs.  NRF-1 increased 
MitoTracker fluorescence 50% more in cyclin D1-deficient cells (Fig. 3C).  In vivo 
association of NRF-1 with cyclin D1 was demonstrated by the mammalian two-hybrid 
system using GAL4-cyclin D1 and VP16-NRF-1 fusion constructs in cyclin D1-/- 3T3 
cells (Fig. 3D).  
Microarray analysis of cyclin D1-/- MEFs transduced with a retroviral expression 
vector for cyclin D1, compared with empty vector identified 210 genes repressed by 
cyclin D1, 73 of which were similar and 18 identical to the putative NRF-1 site 
containing gene promoters (Fig. 3E). As NRF-1 induces genes in a cell-type specific 
manner, we further identified NRF-1-responsive genes in MEFs by transducing cells with 
a retrovirus expressing NRF-1 and conducting microarray analysis.  In these cells 
mitotracker activity was also induced 3-fold (data not shown). Of the 131 genes induced 
by NRF-1 (see supplemental material), 22 genes were similar to cyclin D1-repressed 
genes in MEFs.  
As the Cdk4 binding-deficient mutant of cyclin D1 failed to repress NRF-1-
mediated transcriptional activity, and since NRF-1 is phosphorylated (14), we compared 
GST-pRb and GST-NRF-1 as substrates of cyclin D1/Cdk4 kinase. NRF-1 was 
efficiently phosphorylated by cyclin D1-IP kinase (Fig. 4A).  Cyclin D1 co-transfection 
enhanced 32P-orthophosphate labeled NRF-1 (Fig. 4B, left panel). The p16INK4a peptide 
inhibits cyclin D1-dependent kinase activity and pRb phosphorylation  (15). A p16INK4a 
peptide (P20), with a D92A substitution lowers the IC50 (16) and when linked to the 
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Antennapedia carrier sequence, inhibit pRb phosphorylation ((16) (and data not shown)) 
and NRF-1 phosphorylation (Fig. 4B). The p16INK4a peptide (P21) with a A95/96 
mutation has an increased IC50 for the inhibition of pRB phosphorylation by cyclin-
dependent kinases in vitro (16).  We further showed that it failed to inhibit NRF-1 
phosphorylation (Fig. 4B). A comparison was made between NRF-1 and pRb as 
substrates in cyclin D1-dependent kinase assays. The pRb peptide which contains two 
sites of phosphorylation incorporated γ32P at approximately twice the rate as equal moles 
of NRF-1 (Fig. 4C). Alignment of the major Cdk4 phosphorylation sites of pRb, p130 
and p107 with NRF-1 identified a motif including S47 (Fig. 4D). Point mutation of NRF-
1 S47 reduced phosphorylation by cyclin D1-dependent kinase activity 85% (Fig. 4D, 
right two lanes). In order to determine whether any of the other serine residues within the 
carboxy terminal fragment of NRF-1, which was sufficient for phosphorylation, could 
provide rescue function. Analysis was conducted of Alanine insertion mutants of all 12 
candidate phosphorylation sites (12xA), with reintroduction of single wild type residues 
into the cyclin D1 12xA mutant. The proteins were expressed equally by HA-Western 
blot analysis, but served as poor cyclin D1-dependent kinase activity substrates compared 
to the HA-tagged wild type NRF-1 (Fig. 4D), indicating S47 is necessary but not 




The mechanisms integrating cell-cycle progression and/or exit with mitochondrial 
biogenesis were previously unknown (17, 18).  Herein, we demonstrate cyclin D1 ability 
to repress mitochondrial function and size in vivo.  This novel function of cyclin D1 
represents the first bone fide, non-nuclear function for cyclin D1. We further show that 
the kinase function of cyclin D1 is required for repression of mitochondrial activity and 
for phosphorylation of NRF-1. Cyclin D1 bound NRF-1 in cells assessed either by 
immunoprecipitation western blot analysis or by mammalian 2-hybrid. To provide 
additional corroborative evidence that cyclin D1 inhibited NRF-1-regulated functions, we 
determined the molecular genetic signature regulated by cyclin D1 and compared this 
with putative NRF-1 regulated genes based on genome wide location analysis of 
candidate NRF-1 target genes (19). The genes regulated by cyclin D1, were determined 
by introducing a cyclin D1 expressing retrovirus into cyclin D1-/- MEFs and conducting 
microarray analysis. A comparison of cyclin D1-repressed genes and genes potentially 
regulated by NRF-1, based on analysis of NRF-1 binding sites in their promoters, showed 
substantial overlap (Fig. 3F).  We next compared the molecular genetic signature of 
genes actually regulated by cyclin D1 and those genes actually regulated by NRF-1.  The 
genes regulated by NRF-1 were determined by transducing MEFs with an NRF-1 
expressing retrovirus and conducting microarray analysis. Of the 254 candidate NRF-1-
inducible genes and 210 genes repressed by cyclin D1, 73 similar genes and 18 identical 
genes were shared between the two gene sets.   
 
 10 
We examined the physiological regulation of cyclin D1 and NRF-1 expression. 
NRF-1 was increased 3-fold in cyclin D1 null cells. Cyclin D1 levels and NRF-1 
expression were inversely correlated during cell cycle progression, with serum-induced 
cyclin D1 expression peaking at 12 hours and NRF-1 expression decreasing in 8-12 
hours.   The reduction in NRF-1 abundance at 8 hrs, shortly after cyclin D1 levels 
increased Fig. 2C), was consistent with our model in which cyclin D1 inhibits NRF-1 
function (Fig. 5). Together these studies identified, for the first time, the genes regulated 
by NRF-1 and those NRF-1 regulated genes that showed significant overlap with cyclin 
D1-regulated genes. The prior studies of NRF-1 regulation by serum, in other cell types 
showed no change in levels or activity of cytochrome oxidase and several NRF-1 targets 
within 12 hrs of serum stimulation (20). ChIP assays in Cam et al. show no change in 
NRF-1 binding to NRF-1 sites during serum treatment.  At this time, no NRF-1 
regulatory serum-inducible kinase has been isolated and multiple phosphorylation sites 
do exist in NRF-1, likely regulated by distinct kinases. The finding herein that NRF-1 is 
inactivated by cyclin D1, and phosphorylated by cyclin D1-dependent kinase does not 
preclude the possibility that NRF-1 may be regulated by other serum-regulated kinases, 
as many proteins are under regulation by distinct kinases regulating proliferative and anti-
proliferative signals.  It remains to be determined whether other cell-cycle-regulatory 
kinases phosphorylate and repress NRF-1.  
Cyclin D1 repressed NRF-1 induced genes by microarray analysis.  Additionally, 
cyclin D1 repressed mitochondrial genes that were not considered direct NRF-1 targets as 
defined by either the presence of putative NRF-1 sites in their promoters or by microarray 
analysis in MEFs.  Cyclin D1 expression repressed mtTFA abundance and promoter 
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activity requiring, primarily, the NRF-1 and NRF-2 binding sites. mtTFA binds to 
sequences in the divergent heavy and light-chain promoters of the mitochondrial D-loop 
region where it stimulates transcription from mitochondrial DNA templates. Consistent 
with the finding that cyclin D1 repressed NRF-1 and mtTFA, cyclin D1 inhibited D-loop 
transcriptional activity. mtTFA promotes differentiation in myoblasts (21-23) while 
cyclin D1 inhibits differentiation of myocytes (24) and adipocytes (12). Cyclin D1 
antagonizes NRF-1 and mitochondrial function while inducing DNA synthesis, thereby 
potentially coupling biosynthetic priorities within the cell. 
In this study we proposed that cyclin D1 may integrate cell-cycle progression 
and/or exit with mitochondrial biogenesis (Fig 5). We do in fact demonstrate the 
increased abundance of cyclin D1 led to reduced mitochondrial activity. The outcome of 
reduced mitochondrial activity would be anticipated in order to shift glucose metabolism 
toward cytosolic glycolysis. Whether such a triage of substrate utilization or metabolic 
prioritization occurs in the presence of increased cyclin D1 abundance remains to be 
determined. A shift towards cytosolic glycolysis is known to occur during tumor 
progression and is a component of the metabolic change described by Dr. O. Warberg in 
1930.   Known components of the mitochondria-to-nucleus retrograde pathway include 
CREB, mRpL12, and aconitase, (which produces α-ketoglutarate) (25-27). In 
Drosophila, in which proliferation rates are partially uncoupled from growth, cyclin D1 
induces cell size and Hif-1 prolyl hydroxylase (HPH) activity (25). But in mammalian 
cells, HPH is not required for proliferation by cyclin D1/Cdk4, mitochondria inhibit HPH 
hydroxylase and cyclin D1 does not affect cell size (28, 29).  Mitochondria produce ATP 
(30), regulate single carbon metabolism, fatty acid metabolism and oxidative glycolysis 
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(5) and are a potential target for cancer therapies (31). As cyclin D1 is inhibited by 
differentiation and induced by oncogenes, this new function of cyclin D1 may provide a 
mechanism by which select oncogenes and growth factors contribute to tumor 
maintenance.  
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Materials and Methods: 
Mice 
Mice homozygously deleted of the cyclin D1 gene (cyclin D1-/-) (32) on a mixed 
C57Bl/6x129/SvJ background were maintained as described previously (9). Genotyping 
was performed on tail genomic DNA by PCR under the following conditions: denaturing 
at 96°C for 1 min, followed by 30 cycles of 94°C for 30 sec, annealing at 58°C for 30 
sec, extension at 72°C for 30 sec with a final extension at 72° for 5 min. The cyclin D1 
specific primers were described (32). 
Cell Culture 
Day 5 Bone marrow macrophage (BMM) from cyclin D1+/+ and cyclin D1-/- mice were 
prepared as previously described (33) and cultured in supplemented α-modified minimal 
essential medium (α+MEM) (Life Technologies, Gaithersburg, MD.) containing 15% 
fetal bovine serum (FBS) (Life Technologies) and 120 ng/ml human recombinant CSF-1 
(gift of Chiron Corp., Emeryville, CA). MCF-7 and HEK 293T cells were maintained in 
DMEM containing penicillin and streptomycin (100 mg of each/liter) and supplemented 
with 10% FBS.  
Primary MEFs were isolated following protocol described in (34) from day 14 
post coitus (d.p.c.) mouse embryos. Briefly, embryos were separated and minced and 
then incubated in a solution with 0.05% trypsin and 1 mM EDTA at 37°C. The 
supernatant was collected by centrifugation at 1,000g for 3 minutes.  
Plasmids, transfections and reporter assays 
The expression vectors pCMV-cyclin D1, CMV-cyclin D1-KE, CMV-cyclin D1 GH, 
pCMV-cyclin E, pCMV-cyclin A and RSV- and CMV-Renilla luciferase reporter were 
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previously described (35). The human cyclin D1 mutants were derived by PCR-directed 
amplification using sequence-specific primers and cloned into pRC/CMV. The reporter 
plasmids NRF4-Luc (containing 4 tandem NRF-1 sites) (36), mtTFA-RC4wt/PGL3 (37), 
reporters with NRF-1, NRF-2, or Sp1 mutations (6) and the expression vector pSG5 
NRF-1 (38) were previously described. Wild type and mutant cyclin D1 and NRF-1 
cDNA fragments were inserted into the EcoRI site of the pMSCV-IRES-GFP vector to 
make pMSCV-IRES-GFP-cyclin D1 and pMSCV-IRES-GFP-NRF-1. 
Mammalian two-hybrid was performed following manufacturer’s instructions 
(Promega). Cyclin D1 cDNA was cloned into pBind vector and NRF-1 cDNA was cloned 
into pACT vector to generate fusion proteins with the DNA binding domain of GAL4 
(Gal4-cyclin D1) and the activation domain of VP16 (VP16-NRF-1), respectively. The 
pG5Luc vector contains five GAL4 binding sites upstream of a minimal TATA box, 
which in turn, is upstream of the firefly luciferase gene. 
DNA transfection and luciferase assays were performed as previously described 
(39). Cells were transfected by Superfect Transfection reagent (Qiagen, Valencia, Ca). 
The medium was changed after 5 h, and luciferase activity was determined after 24 h. At 
least two different plasmid preparations of each construct were used. In cotransfection 
experiments, a dose-response curve was determined in each experiment with 20 ng of 
expression vector and the promoter reporter plasmids (1 µg). Luciferase activity was 
normalized for transfection with Renilla luciferase reporter (Promega) as an internal 
control. Luciferase assays were performed at room temperature with an Autolumat LB 
953 (EG&G Berthold). The -fold effect was determined by comparison to the empty 
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expression vector cassette, and statistical analyses was performed using the Mann 
Whitney U-test. 
Cytochemistry and electron microscopy 
 Liver and mammary gland from cyclin D1 wt and cyclin D1-/- mice were removed under 
anesthesia. Slices (approximately 2 mm thick) were prepared by hand cutting with a razor 
and were immediately placed into cold fixative consisting of a mixture of 4 % 
paraformaldehyde and 2.5% glutaraldehyde in 0.1M cacodylate buffer, pH 7.4 for 3hrs 
with continuous skaking. Non-frozen sections (~20 µm) of the aldehyde fixed tissue 
slices were prepared using a Lancer vibratome sectioning instrument (Polysciences, 
Warrington PA). Sections were tested for catalase activity using an incubating medium 
containing 3, 3” diaminobenzidine tetrahydrochloride (Sigma) as a substrate at pH 9.7 to 
visualize peroxisomes and microperoxisomes.  The incubated sections were then fixed in 
1% osmium tetraoxide (Polysciences), alcohol dehydrated and embedded in Epon. 
Ultrathin sections (approximately 500 angstroms) were prepared using a LKB 
ultramicrotome (LKB, Sweden), stained with lead citrate and examined with a Philips 
300 electron microscope (40).  All pictures were taken at the same magnification, i.e at 
5000X.  To determine mitochondrial size and number, stereology was performed 
according to the method of Weibel (12). A grid of approximately 1cm squared was 
placed over each print photo (magnificatoin of 13,500X) and mitochondria within the 
grid were counted.   
FACS analysis 
Bone marrow macrophages, hepatocytes, and MEFs derived from cyclin D1+/+ and cyclin 
D1-/- mice were incubated in medium containing 50 nM of MitoTracker Deep Red 633 
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(Molecular Probes) for 30 min at 37°C. Cells were then trypsinized and resuspened in 
PBS. The MitoTracker fluorescence of these positive cells was analyzed by flow 
cytometry. 
Western Blot 
The antibodies used in Western blot analysis were cyclin D1 antibody Ab3 (NeoMarkers 
Lab Vision Corporation, Fremont, CA), cyclin D1 antibody 72-13G, PGC-1 (H-300) 
(Santa Cruz) and NRF-1 (Felorence). Proteins were visualized by the enhanced 
chemiluminescence system (Amersham Pharmacia Biotech, Piscataway, NJ). The 
abundance of immunoreactive protein was quantified using a densitometer (Image Quant 
version 1.11, Molecular Dynamics Computing Densitometer, Sunnyvale, CA).   
Retroviral infection and FACS sorting 
Retroviruses were prepared as described previously (32). Briefly, pMSCV-IRES-GFP 
was co-transfected with an ecotropic, replication-defective helper virus pSV- —E-MLV 
into 293T cells, by calcium phosphate precipitation. The retroviral supernatants were 
harvested 48 h after transfection and filtered through a 0.45-µm filter. cyclin D1-/- MEFs 
were incubated with fresh retroviral supernatants and 8 µg/ml polybrene,  centrifuged for 
2 hours at 1200 rpm at 25°C and incubated at 37°C overnight. Following 2 days of 
culture in DMEM with 10% FBS, GFP positive cells were sorted by FACStar (Beckton 
Dickinson). 
High Density Array Expression Analysis  
Total RNA was isolated from retrovirus vector infected MEFs (infected with either 
MSCV- IRES-GFP vector or MSCV-IRES-FLAG-NRF-1) using Trizol.  Total RNA was 
used to probe an Affymetrix GeneChip® Mouse Expression Set 430 array (Affymetrix, 
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Santa Clara, CA). RNA quality was determined by gel electrophoresis. Probe synthesis 
and hybridization was performed according to the manufacturer's protocol (see eukaryotic 
target preparation section at http://www.affymetrix.com/support). Three arrays were used 
for each condition. Analysis of the arrays was performed as described (41). 
In vivo labeling 
293T cells were plated 24 h before transfection. Prior to transfection, cells were washed 
incubated with phosphate-free DMEM medium for 2 h, and then 32P-orthophosphate was 
added to the cell culture medium at 1 mCi/ml. Lysates were prepared and precipitated 
with M2 antibody for at least 6 h. Beads were washed with 6 changes of lysis buffer and 
protein-bound beads were denatured in SDS buffer. Protein was resolved by SDS-PAGE 




Figure 1. Cyclin D1-deficiency enhances mitochondrial size and function. (A, B). 
Transmission electron microscopic (TEM) images of hepatocytes from liver tissue of 
cyclin D1+/+, left in (A) and (B, red box, enlarged area) and cyclin D1-/- right images in 
(A) and (B, yellow box, enlarged area) show increased mitochondria size in cyclin D1-/ - 
mice. Catalase-positive peroxisomes (dark spherical structures) are evident in (A). 
Magnification:  (A) original, 5000X.   (C, D). Mitochondrial size is increased in 
proportion to cellular cytoplasm shown through stereoscopy in cyclin D1-/- and in cyclin 
D1+/+ hepatocytes. (E) TEM of mammary gland adipocytes with enlarged view (F), 
reveals increased mitochondria size. (G). Mitochondrial activity in hepatocytes (Ga), 
Bone Marrow Macrophages (Gb) and MEFs (Gc) derived from either cyclin D1+/+ or 
cyclin D1-/- mice assessed using MitoTracker (Deep Red, 50 nM).  
Figure 2. NRF-1 activity is enhanced in cyclin D1-deficient cells. (A) Vectors 
encoding cyclin D1 Wt and mutants in the vector MSCV-IRES-GFP were used to 
transduce cyclin D1-/- MEFs for a week. Cells were stained with Mitotracker Red CMX 
Ros for 30 min. The GFP positive cells were sorted and MitoTracker fluorescence and 
cell cycle was analyzed by flow cytometry. The cyclin D1 K112 residue was required for 
inhibition of Mitochondrial activity and induction of DNA synthesis. (B, C). MCF-7 cells 
were starved in DMEM supplemented with 0.2% FBS for 48 hours. Cells were harvested 
at time points as indicated. Total cell lysates were prepared and subjected to Western 
blotting analysis to detect cyclin D1 and NRF-1 expression. β-tubulin and GDI were 
included as loading controls. (D, E) Cyclin D1+/+ and cyclin D1-/- 3T3 cells were 
transfected with vectors in which the reporter activity was driven by the various 
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promoters driving luciferase reporter genes for wild type mtTFA, D-loop, or CMV or (F) 
mtTFA promoter reporter plasmids encoding mutant response elements for NRF-1, Sp-1, 
or NRF-2. The luciferase activity is shown as the mean ± SEM (N≥6). (G) MCF-7 cells 
were transfected in 24-well plates with 1 µg of a luciferase reporter gene containing four 
copies of NRF-1 response elements, 0.5 µg of pSG5 vector or pSG5-NRF-1 expression 
plasmid and the cyclin D1 expression vector. Luciferase activity was normalized to a co-
transfected pRL-TK Luc control. (H) Mutant cyclin D1 expression plasmids were 
compared for NRF-1 repression function. (mean ± SEM, N>3 separate experiments, each 
performed in quadruplicate).   
Figure 3. Cyclin D1 interacts with NRF-1. (A) Lysates from mouse liver were 
subjected to cyclin D1 antibody immunoprecipitation (IP). IP products were resolved on 
SDS-PAGE gel with Western blot to NRF-1 or PGC-1.  Cyclin D1 associates with NRF-
1, but not PGC-1 in vivo. (B) 293T cells were transfected with FLAG-tagged NRF-1 and 
cyclin D1. Cell lysates were subjected to IP with either IgG or anti-FLAG antibody. IP 
products were resolved on SDS-PAGE gel followed by Western blot with either FLAG, 
for NRF-1, or cyclin D1 antibodies. (C) Vectors encoding NRF-1 (in the vector MSCV-
IRES-GFP) were used to transduce cyclin D1-/- and cyclin D1+/+ MEFs. Cells were 
stained with MitoTracker Red CMX Ros for 30 min. The GFP positive cells were sorted 
and MitoTracker fluorescence analyzed by flow cytometry. (D) The Gal4-cyclin D1 and 
VP16-NRF-1 fusion constructs were transfected with the pG5luc reporter into cyclin D1-/- 
3T3 cells. Firefly luciferase activity was quantitated using the Dual-Luciferase® Reporter 
Assay System (Promega). Interaction between these two proteins (lane 7) increased 
luciferase activity compared to negative controls. (E) Comparison of cyclin D1-regulated 
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genes as determined by microarray analysis with genome wide location analysis of 
candidate NRF-1 target genes comparing genes found on the HU13K and MGU74 chips 
(http://www.jci.tju.edu/pestell/papers/gfp_vs_d1.xls and http://www.jci.tju.edu/pestell/ 
papers/gfp_vs_nrf1.xls) (19). 
Figure 4. NRF-1 serves as substrate of cyclin D1-dependent kinase. (A) GST-NRF-1 
was incubated with an immunoprecipitated cyclin D1/Cdk4 kinase complex in the 
presence of 32p-γ-ATP. Left panel: coomassie blue staining of input GST protein; Right 
panel: γ32p incorporation into GST-NRF-1. GST and GST-Rb were the negative and 
positive controls for kinase activity. (B) Left panel: 293T cells were transfected with 
FLAG-NRF-1 and cyclin D1 or control empty vector. Right panel: 293T cells transfected 
with FLAG-NRF-1 and cyclin D1 were treated with p16INK4a peptide (20 µM) 
corresponding to amino acids 84-103 of the human p16INK4a protein 
(DAAREGFLATLVVLHRAGAR), with a C-terminal 16 amino acids Penetratin 
(RQIKIWFQNRRMKWKK) or control peptide. (Bio-synthesis, Inc. Lewisville, TX), 
(42). NRF-1 phosphorylation was abrogated by the p16INK4a peptide. Cells were pulse-
labeled with γ32P-orthophosphate. NRF-1 protein was precipitated with anti-FLAG M2 
antibody and subjected to autoradiography. (C) Equal amounts of either the GST-NRF-1 
N70 fusion protein or GST protein were incubated with 200 ng of purified cyclin 
D1/Cdk4 complex and [γ32P]-ATP (left panel). In the autoradiogram the arrows indicate 
the phosphorylated fusion protein. GST-Rb serves as a positive control. The 
phosphorylated bands were quantified by densitometry scanning (right panel). (D) 
Alignment of Cdk4 phosphorylation sites for pRb, p107, p130 and NRF-1. 293T cells 
were transfected with expression vectors encoding HA or FLAG-tagged NRF-1 and 
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mutants along with cyclin D1-NRF-1 mutants included one in which a single potential 
phosphorylation site was restored in all sites (12xA) or one with a single point mutant of 
S47.  NRF-1 and mutant proteins were precipitated with anti-HA antibody and subjected 
to autoradiography. 
Figure 5. Schematic representation of the mechanism by which cyclin D1 inhibits 
mitochondrial function. Cyclin D1-dependent kinase phosphorylates and inhibits NRF-
1 and thereby mtTFA and mitochondrial activity. Additional NRF-1-independent 
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Supplemental material. Tree view display of microarray analysis and Mitotracker 
analysis of MEFs transduced with NRF-1 retrovirus. 
 
